Feb 2, 2021 by Jason HawthorneIs Pacific Biosciences of California a Ticking Time Bomb for Investors?A new leadership team is betting that it can make long-read genome sequencing more competitive.
Jan 30, 2021 by Jason HawthorneFiverr in 5 ChartsThese pictures tell the story of accelerating growth and a march to profitability.
Jan 29, 2021 by Jason HawthorneDanger Lurks for These 3 High-Yield Dividend StocksGreat dividends need to be sustainable, and that requires free cash flow.
Jan 26, 2021 by Jason HawthorneIs Pfizer A Great Dividend Stock?Three metrics can help answer the question.
Jan 26, 2021 by Jason HawthorneCould Pfizer Be a Millionaire-Maker Stock?Recent guidance from the CEO suggests this stock will beat the market over the next decade.
Jan 24, 2021 by Jason Hawthorne3 Reasons This Hot Stock May Not Survive 2021This promising cancer fighter might sell out this year to cash in on its potential.
Jan 19, 2021 by Jason HawthorneWall Street Couldn't Stop Buying Shares of These 2 Stocks in 2020These stocks could be set for big gains in 2021 even after huge returns last year.
Jan 16, 2021 by Jason HawthorneWall Street Was Busy Selling These 2 Stocks in 2020Investors holding shares in these two companies need to practice patience.
Jan 15, 2021 by Jason HawthorneIf You Invested $10,000 in BioNTech in January, This Is How Much You'd Have NowYou have to take some risk if you expect to get the reward.
Jan 15, 2021 by Jason HawthorneForget Snowflake! Buy This Ultra-High-Growth StockThis business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.
Jan 15, 2021 by Jason Hawthorne2 Recent IPOs to Watch in 2021A key metric for each company can signal investors that their growth stories are beginning to sour.
Jan 13, 2021 by Jason HawthorneHere's Why You Should Really Own Repligen in 2021The tailwinds behind the company's gains aren't going anywhere.
Jan 12, 2021 by Jason HawthorneCould This Be the Biggest IPO In 2021?A social network with accountability might be the IPO to buy this year
Jan 12, 2021 by Jason Hawthorne1 Big Reason Trillium Therapeutics Stock's Hot Streak Will Continue in 2021When it comes to countering a key trick that cancer plays on the human immune system, this biotech has no equal.
Jan 11, 2021 by Jason HawthorneIf You Invested $10,000 in Moderna in January, This Is How Much You'd Have NowHuge gains in the stock can teach investors a valuable lesson
Jan 9, 2021 by Jason HawthorneThese Were the 5 Best Diagnostics Stocks of 2020These winners are positioned for gains even after COVID.
Jan 8, 2021 by Jason HawthorneUp 1,530% in 2020, Is Vaxart Still a Buy?The biotech stock could still have big gains ahead, and not just because of its COVID-19 vaccine candidate.
Jan 7, 2021 by Jason Hawthorne3 International Companies Whose Products You Probably Use Without NoticingIt's easy to overlook that plenty of great businesses were born elsewhere. Some of the best get missed because they operate in the background.
Jan 6, 2021 by Jason Hawthorne3 Things to Expect from OPKO Health in 2021It's the perfect time for a wealthy CEO to ride off into the sunset.
Jan 6, 2021 by Jason HawthorneIs Pfizer Stock a Buy?The company is poised to begin delivering on its promise of growth and innovation.
